Adare Pharma Solutions, a global contract development and manufacturing organization (CDMO) focused on oral dosage forms, completed its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty. The transaction represents an enterprise value of €275 million.

dsm-firmenich intends to extend the availability of Lactéol, Adare Biome’s over the counter postbiotic supplement for relieving gut upsets, through its B2C unit, i-Health.

Tom Sellig, CEO of Adare Pharma Solutions, said, “dsm-firmenich is the ideal company to take Adare Biome to the next level and realize the growth potential of postbiotics. They have the infrastructure, together with strong commercialization and science capabilities, to scale the significant scientific research that we’ve achieved over the years. This divestiture will provide Adare Pharma Solutions with additional resources for our core CDMO business and allow us to further grow our position as a world-class outsourcing partner to the pharmaceutical industry.”

Philip Eykerman, dsm-firmenich’s President Health, Nutrition & Care, said, “Adare Biome, as a global leader in the research and manufacturing of postbiotics with over a century of pioneering science in its heritage, is a perfect fit for dsm-firmenich that will complement three of our four Business Units. The Adare Biome teams bring great knowledge in this area which will greatly help in driving our ‘Health from the Gut’ strategy and enable us to accelerate the creation of next-generation biotics to support the health of people and animals.”